Jianzhao Zhang
Key Laboratory Of Molecular Pharmacology And Drug Evaluation
Yantai, 264005, China
Yantai, 264005, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Preclinical and Toxicology Studies of LPM7100328, a Novel Oral GnRH Antagonist.
Journal: Pharmacology research & perspectives
Published: February 22, 2026
TAAR1-mediated pathways regulating nigrostriatal function and the discovery and pharmacological characterization of a novel TAAR1 agonist, Selutaront.
Journal: Frontiers in pharmacology
Published: December 03, 2025
Discovery of a novel Nrf2 activator that modulates mitochondrial function in neurons by regulating DHRS3-Nrf2 interaction after ischemic stroke.
Journal: Theranostics
Published: November 18, 2025
Targeting RIPK1-mediated necroptosis, oxidative stress, and ferroptosis: A novel multitarget therapy for ischemic stroke.
Journal: European journal of medicinal chemistry
Published: May 01, 2025
Development of a Highly Potent Neurokinin‑3 Receptor Inhibitor: Design, Synthesis, and Evaluation.
Journal: ACS medicinal chemistry letters
Published: April 28, 2025
Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT2C Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer's Disease-Related Psychosis.
Journal: Journal of medicinal chemistry
Published: March 31, 2025
Synthesis and evaluation of novel 5-HT2A receptor inverse agonist with excellent in vivo antipsychotic efficacy and superior tissue distribution for treatment of Parkinson's disease psychosis.
Journal: European journal of medicinal chemistry
Published: March 11, 2025
Ferroptosis in Ischemic Stroke and Related Traditional Chinese Medicines.
Journal: Molecules (Basel, Switzerland)
Published: June 20, 2024
Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Journal: European journal of medicinal chemistry
Published: January 21, 2024
Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53.
Journal: Molecules (Basel, Switzerland)
Published: January 03, 2024
Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment.
Journal: Frontiers in pharmacology
Published: February 09, 2023
Last Updated: 09/26/2026